๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Halothane-caffeine contracture testing in neuromuscular diseases

โœ Scribed by Dr. Terry D. Heiman-Patterson; Henry Rosenberg; Jeffrey E. Fletcher; Dr. Albert J. Tahmaoush


Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
448 KB
Volume
11
Category
Article
ISSN
0148-639X

No coin nor oath required. For personal study only.

โœฆ Synopsis


The association of malignant hyperthermia (MH) with neuromuscular disorders has been recognized since 1970. These disorders include central core disease, Duchenne muscular dystrophy, myotonia congenita, myotonic dystrophy, nonspecific myopathies, and King-Denborough syndrome. In order to assess the anesthetic risk of MH in the neuromuscular population, we performed halothane and caffeine contracture testing for MH susceptibility on biopsied muscle removed from 25 consecutive neuromuscular patients during diagnostic evaluation. Positive contracture tests were found in 7 of 18 patients with myopathic disorders and 3 of 7 patients with neurogenic disorders. Two of our patients had anesthetic events suggesting MH. These findings suggest that myopathic and neuropathic disorders share pathogenic mechanisms with MH, resulting in positive contracture tests and possibly leading to clinical events during anesthesia. Although there is controversy regarding the interpretation of a positive contracture test, contracture testing remains the most widely accepted test for MH susceptibility. Thus, a variety of neuromuscular disorders may be associated with MH susceptibility, and caution should be exercised during anesthesia in this group of patients.


๐Ÿ“œ SIMILAR VOLUMES


RYR1 mutations causing central core dise
โœ Rachel L. Robinson; Collin Brooks; Sarah L. Brown; F. Richard Ellis; P. Jane Hal ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 170 KB

Malignant hyperthermia (MH) and central core disease (CCD) are autosomal dominant disorders of skeletal muscle. Susceptibility to MH is only apparent after exposure to volatile anesthetics and/or depolarizing muscle relaxants. CCD patients present with diffuse muscular weakness but are also at risk